Improving prostate cancer classification using MRI and AI
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
This study is testing whether using advanced MRI scans and artificial intelligence can help doctors better identify and classify prostate cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 275 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT04765150 on ClinicalTrials.gov |
What this trial studies
This study evaluates the integration of advanced magnetic resonance imaging (MRI) techniques and artificial intelligence to enhance the accuracy of prostate cancer diagnosis. It aims to develop quantitative analysis methods that reduce variability in MRI results and improve the detection of clinically significant prostate cancer. The study involves both retrospective review of medical records and prospective MRI imaging sessions at UCLA. By utilizing multi-class deep learning models, the research seeks to systematically analyze MRI features for better classification of prostate cancer.
Who should consider this trial
Good fit: Ideal candidates include male patients aged 18 and older with a clinical suspicion or biopsy-confirmed prostate cancer who are undergoing multi-parametric 3T MRI.
Not a fit: Patients with contraindications to MRI or gadolinium contrast agents, or those who have received prior radiotherapy, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and less invasive diagnostic techniques for prostate cancer.
How similar studies have performed: Other studies have shown promise in using advanced imaging and AI for cancer diagnosis, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male patients 18 years of age and older * Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer * Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA) * Ability to provide consent Exclusion Criteria: * Contraindications to MRI (e.g., cardiac devices, prosthetic valves, severe claustrophobia) * Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent * Prior radiotherapy
Where this trial is running
Los Angeles, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Kyung H Sung, PhD — UCLA / Jonsson Comprehensive Cancer Center
- Study coordinator: Nashla Barroso
- Email: nbarroso@mednet.ucla.edu
- Phone: (310) 794-7952
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.